Dear friends of MVMD,
I wanted to take a moment to personally share an update following several important developments across the business, including the recent closing of our financing, the appointment of a significant new advisory group, and continued progress across our core commercial priorities.
Over the past several months, our team has been highly focused on strengthening the foundation of MVMD, improving our balance sheet, refining our execution strategy, and ensuring that the next phase of growth is built on continued discipline, strong alignment, and the right long-term decisions.
As you may have seen in recent media releases, we recently closed a non-brokered private placement for gross proceeds of CAD $2,000,000, alongside concurrent shares for debt transactions. This was an important step for MVMD. It materially strengthened our balance sheet, and gives us much better flexibility to execute across our priority business lines.
What was particularly encouraging to me was that this recent financing was completed with predominantly new investors. I believe that reflects growing recognition of the value and potential of our technology platforms and the real progress being made across the business. It also reinforces my view that when we execute properly and stay disciplined, the right people take notice.
We also recently announced the appointment of a new advisory group that I believe significantly strengthens MVMD’s ability to execute. This group brings deep expertise across formulation science, regulatory strategy, commercialization, agriculture, capital markets, and business development. Their collective experience directly supports our priorities across Quicksome™, Agrarius™, Quicksol™, and our broader peptide and repurposed therapeutic initiatives. I have included the advisors and their brief biographies below my signature in this update. I encourage you to take a moment to review the strength and depth of this highly talented group, and I believe you will share my excitement and gain a clearer sense of the scale of what we are building toward.
I have always believed that execution matters more than presentation. Advisors do not build businesses, but the right people around the table absolutely improve speed, decision-making, and access to opportunity. I believe this group helps accelerate all three.
Across the business, we continue to make meaningful progress.
In human health and nutraceuticals, Quicksome™ continues to advance through both licensed products and new formulation opportunities. Our recent work with large compound pharmacy groups has become an increasingly important focus, particularly around peptide-based delivery opportunities and broader molecule applications where needle-free delivery creates meaningful commercial value. This builds on our previous FDA work regarding stability and the ability to move sensitive molecules from refrigerated cold chain requirements to room temperature storage and has the potential to create significant differentiation for Quicksome™. These discussions continue to advance well and represent what I believe could become one of the most important near-term growth drivers for the Company.
At the same time, our peptide development work continues to expand with increasing clarity around commercialization pathways, particularly as recent regulatory developments in the U.S. continue to shape the landscape for compounded peptides and broader peptide-based therapeutics. These changes are creating both new opportunities and important compliance considerations, especially across cross-border markets involving the U.S. and Latin America. We are approaching these opportunities with a clear focus on strong regulatory positioning, the right strategic partners, and efficient capital deployment. The opportunity is significant, and our priority is to move decisively while ensuring the foundation is built for long-term success.
I continue to believe our Agrarius agricultural technology represents one of the most important long-term growth opportunities inside MVMD. Our recent work with the Agrarius team has focused on strengthening product quality, improving security standards, and enhancing chain-of-control protections across LATAM. These measures are designed to reduce counterfeit risks, protect product integrity from manufacturing through end-user delivery, and support expanded manufacturing scale for broader commercialization. These efforts help position the business for more efficient growth, scaled customer adoption, and a more durable long-term operating foundation.
The underlying field results and customer interest continue to reinforce my confidence in Agrarius. Our focus remains disciplined commercialization supported by product quality, strong trial validation, and the right funding structure to support growth across LATAM.
Our Quicksol™ platform also continues to present meaningful long-term optionality across both husbandry and broader pharmaceutical applications. While we remain disciplined on capital deployment, we continue to evaluate opportunities in areas such as oncology, antivirals, and future delivery models that can create significant strategic value over time.
As we move through 2026, our focus is very clear: execution, commercialization, and disciplined growth.
In concert with our operational progress, we are also actively reviewing broader strategic opportunities for the Company, including uplisting pathways that better reflect the scale of the business we are building and improve access to long-term institutional capital. We have been evaluating these opportunities for some time and believe this will become a near-term priority to ensure proper long-term capitalization while expanding access to larger institutional investor bases. These decisions require discipline, preparation, and the right timing, but they remain an important part of our forward strategy and something we are actively planning for.
I believe this year represents a meaningful step forward and a strong foundation for what comes next. We are operating from a stronger financial position, with better alignment across the team, stronger external support, and increasing confidence in our commercial path forward.
As you can imagine, the team has been working extremely hard to put MVMD in a healthy position to capitalize on our assets and the foundational work completed to date, and I am very proud of what has been accomplished. There is still a lot of exciting work ahead, but I believe we are moving forward with the right people, the right priorities, and a much stronger foundation.
Thank you for your continued trust, patience, and support as we continue building MVMD and advancing our vision of More Life, creating better health, longer lives, and greater access to meaningful innovation for people around the world.
Advisory Group
Aubrey Marcus
Founder of Onnit, which he scaled to a nine-figure exit, and a recognized leader in human performance and wellness. Aubrey is a New York Times bestselling author and host of a widely followed podcast, with a demonstrated ability to translate emerging health technologies into broad consumer adoption. His experience in branding, storytelling, and distribution, combined with an extensive network across entrepreneurs, athletes, and investors, supports strategic partnerships, capital alignment, and market positioning.
Bode Miller
Olympic gold medalist and one of the most decorated alpine skiers in history, known for precision, resilience, and elite performance. Bode has expanded into entrepreneurship, agriculture, and wellness, with direct involvement in farming and land-based systems. He brings a practical perspective on performance optimization and agricultural innovation, along with relationships across sports, investment, and regenerative food systems.
Shawn Wells
Widely regarded as a leading formulator in the nutraceutical industry, Shawn Wells is a nutritional biochemist behind numerous commercially successful ingredients and products. He holds multiple patents across ingredients and formulations and has worked with many global supplement brands. His expertise in bioavailability, ingredient innovation, peptide science, and regulatory strategy supports product development and scalability, with a focus on optimizing stability, delivery systems, and real-world efficacy.
Emily Kaplan
Emily Kaplan is an entrepreneur, operator and strategic communications expert operating at the intersection of health innovation, science literacy, and business growth. As CEO and Co-founder of MetFix, a national network of 150+ brick-and-mortar affiliate locations deploying evidence-informed metabolic health protocols and the Broken Science Initiative, she has built a two-pronged platform addressing the root cause of the chronic disease epidemic. As founder of The Kleio Group, she advises politicians, celebrities, and CEOs through crisis, launch, and strategic pivots. A 2x HarperCollins business author and former producer for ABC News' 20/20, Primetime, and Good Morning America, she has been featured in The Wall Street Journal and The New York Times. Emily brings two decades of experience translating complex science and high-stakes narratives into clear, actionable strategy. She is a recognized voice in performance health and alternative health ecosystems, known for identifying early-stage breakthroughs and the influence to move them forward.
Janet Zand
Dr. Janet Zand is a pioneer in integrative medicine with decades of experience combining conventional and complementary therapies. She has been actively involved in exploring and advancing repurposed therapeutics within broader treatment frameworks. She is a co-founder and formulator for Zand Formulas, Humann and Pure BioHealth. She was the lead researcher on the first published, researched nitric oxide nutraceutical, which has now had over 1.5 million doses administered. Dr. Zand brings seasoned clinical expertise, regulatory awareness, and a patient-centered approach, strengthening the Company’s credibility across both medical and consumer health landscapes.
Mark Gelnaw
Mr. Gelnaw is a senior financial executive with more than 35 years of experience in financial management, corporate strategy, and business leadership. He has served as Chief Operating Officer of Deutsche Bank and Chief Operating and Financial Officer at Lehman Brothers, and held senior roles at Salomon Brothers and Arthur Andersen. He also acted as CEO and CFO of Cynvec LLC, a cancer research company partnered with NYU. Mr. Gelnaw sits on numerous business advisory boards for both profit and non-profit organizations and is the founder of Breakwater Ventures, which manages investments across multiple sectors including healthcare, technology, and financial services.
Alex Wolfe
Alex Wolfe is a founder, operator, and brand builder with over 12 years of experience in regulated and emerging markets, including psychedelics and nutraceuticals. As the founder of Eons, a global health and wellness company focused on functional mushroom-based products, he works to combine adaptogenic compounds with advanced biotechnology platforms, including MVMD’s Quicksome™ technology, to support the development of differentiated consumer health products. He brings experience in business development, commercialization, and market positioning, with a focus on scaling innovative technologies in high-growth categories.
Dan Engle
Dr. Dan Engle is a board-certified psychiatrist with expertise in integrative mental health and emerging therapeutic approaches, including psychedelic-assisted therapy. He has extensive experience working with trauma, veterans, and high-performance individuals, bridging conventional psychiatry with evolving treatment modalities. Dr. Engle contributes clinical perspective, ethical oversight, and domain expertise in neurological and mental health innovation.
Domingos S. S. Junior
Domingos S. S. Junior is the founder and lead investor at DSJ Capital, a U.S.-based private equity firm. He brings more than two decades of experience across pharmaceutical, cosmetic, food, and medical device industries, with deep expertise in regulatory affairs, quality systems, and manufacturing operations. Domingos previously served for over 20 years at ANVISA as a Senior Regulatory Affairs Specialist, with experience in GMP inspections, regulatory policy, and international coordination, including participation in ICH forums. His background supports regulatory strategy, manufacturing scale-up, and international market development.
Luis Felipe Scarpa Street
Luis Felipe Scarpa Street is an investor and entrepreneur with over 25 years of experience across financial services, biotechnology, and industrial ventures. He co-founded and managed a Brazilian hedge fund later acquired by Bradesco and has held executive leadership roles in marketing and business development. He is currently Chief Business Development Officer at Tecbio and co-founder of Biogrowth do Brasil. His experience spans capital markets, biotechnology commercialization, and industrial applications, supporting business capitalization and strategic growth initiatives.
